Tarpeyo gains full approval
The FDA granted full approval to Tarpeyo for primary immunoglobulin A nephropathy, marking the product’s transition from accelerated or conditional pathways to a standard approval. The decision was reported as the first full approval in that disease. (managedhealthcareexecutive.com)
Immunoglobulin A nephropathy is a kidney disease in which antibody clumps lodge in the kidneys’ tiny filters and leave blood and protein in the urine. On December 20, 2023, the Food and Drug Administration converted Tarpeyo to a standard approval for adults at risk of progression. (niddk.nih.gov) (accessdata.fda.gov) Tarpeyo is a delayed-release form of budesonide, a steroid, and the updated label says it is used to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy. The drug had first reached the market in December 2021 under the Food and Drug Administration’s accelerated pathway on the basis of lower protein in the urine, a surrogate marker. (accessdata.fda.gov 1) (accessdata.fda.gov 2) The confirmatory evidence came from the phase 3 NefIgArd trial, which enrolled 364 adults with biopsy-proven disease on optimized renin-angiotensin system inhibitor therapy. After two years, estimated glomerular filtration rate fell by 6.11 milliliters per minute per 1.73 square meters with Tarpeyo versus 12.0 with placebo. (thelancet.com) (calliditas.se) That shift matters in kidney disease because estimated glomerular filtration rate is a direct measure of how fast the kidneys are losing filtering capacity, while protein in the urine is an earlier signal. Kidney News said the December 2023 decision made Tarpeyo the first fully approved Food and Drug Administration treatment for immunoglobulin A nephropathy based on kidney function. (kidneynews.org) (thelancet.com) The disease itself starts in the immune system and injures the kidney’s filters over time. The National Institute of Diabetes and Digestive and Kidney Diseases says those antibody deposits can scar nephrons, the kidney’s working units, and lead to chronic kidney disease. (niddk.nih.gov) Tarpeyo is designed to open in the ileum, a section of the small intestine, where immune tissue called Peyer’s patches helps produce the abnormal immunoglobulin A linked to the disease. The Food and Drug Administration label and Kidney News both describe the drug as targeting mucosal B cells in that area. (accessdata.fda.gov) (kidneynews.org) The approved regimen is 16 milligrams once daily in the morning for nine months, followed by a two-week taper to 8 milligrams daily. The label lists common side effects including peripheral edema, hypertension, muscle spasms, acne, headache, upper respiratory tract infection, and weight gain. (accessdata.fda.gov) (tarpeyohcp.com) Treatment for immunoglobulin A nephropathy no longer stops at blood-pressure drugs and supportive care alone. By the time Tarpeyo won full approval, clinical guidance and reviews were already placing targeted-release budesonide alongside renin-angiotensin system blockers and newer kidney-protective medicines for patients with persistent proteinuria. (jamanetwork.com) (thelancet.com) The approval closed the loop on a two-step regulatory path: lower proteinuria opened the door in 2021, and slower kidney-function decline kept the drug there in 2023. For patients with a disease that can progress silently for years, the Food and Drug Administration’s standard approval put the evidence on the harder endpoint. (accessdata.fda.gov 1) (accessdata.fda.gov 2)
